Quick Cox-2, Tysabri responses could signal new industry safety actions

03/1/2005 | Reuters

Coming fresh on the heels of perceived problems concerning Cox-2 inhibitors, the decision by the drug's makers and the FDA to withdraw Tysabri from the market soon after the death of a patient could signal the beginning of an era of faster responses to safety and legal problems drugs may cause. A member of the Washington Analysis research group said the "semi-hysteria over drug safety" probably had as much influence on the response as anything else.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY